Skip to content

To Determine the Effect of a drug, Remifentanil on the Onset Time of a muscle relaxant named Rocuronium using a Monitor in Patients Undergoing General Anaesthesia

To Determine the Effect of Remifentanil Dose on the Onset Time of Rocuronium Using TOF (Train-of-Four) Neuromuscular Monitoring in Patients Undergoing General Anaesthesia - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/02/080283
Enrollment
75
Registered
2025-02-10
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K802- Calculus of gallbladder without cholecystitis

Interventions

Intervention1: Remifentanil (Group R 1.0): 25 patients will be given Remifentanil infusion at a dose of 1 microgram/kg/minute during induction. Intervention2: Remifentanil (Group R 0.5): 25 patients w

Sponsors

KPC Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients planned for any surgery requiring endotracheal intubation under general anaesthesia 2. Patients aged between 18 to 60 years 3. Patients with ASA grade I and II 4. Patients giving informed written consent

Exclusion criteria

Exclusion criteria: 1. Patients with a history of cardiac, pulmonary, renal, hepatic, cerebral or neuromuscular disease 2. Having an allergy to opioids or propofol 3. Chronic alcohol or drug abuse 4. A body mass index of 30 kg/m2 5. Pregnant patients 6. Age less than 18 years or more than 60 years

Design outcomes

Primary

MeasureTime frame
To determine the times taken to reach TOF 0 and TOFR 25% in groups R 0.5, R1 and S and to compare the results and therefore determine the optimal dose of Remifentanil infusion. Timepoint: TOF baseline, TOFR 25% and TOF 0

Secondary

MeasureTime frame
To monitor hemodynamic response to laryngoscopy and intubation.Timepoint: Recorded at Baseline, at TOFR 25% and TOF 0

Countries

India

Contacts

Public ContactDr Subrata Ray

KPC Medical College & Hospital

raysubrata62@gmail.com9674330016

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026